MedPath

Tagged News

MD Anderson Partners with HealthEx to Transform Patient Data Consent Using AI-Driven Platform

AI
  • The University of Texas MD Anderson Cancer Center and HealthEx announced a strategic collaboration to develop AI-driven tools that streamline patient consent processes while giving patients greater transparency and control over their data usage.
  • The partnership will implement HealthEx's artificial intelligence-driven global consent and data rights management platform to enable fast, compliant and patient-centric data access for cancer research.
  • Healthcare institutions generate vast amounts of patient data, but complex consent processes create significant barriers that burden patients with lengthy forms and create labor-intensive workflow challenges.
  • The AI-powered platform will help organizations create, curate and enforce patient consents while creating automated workflows to ensure compliance with patient preferences and institutional policies.

Trinity Life Sciences Partners with Ontada to Enhance Real-World Oncology Data Analytics for Drug Development

OncologyAI
  • Trinity Life Sciences has formed a strategic collaboration with Ontada, a McKesson business, to provide life sciences companies with real-time oncology insights for pre- and post-launch decision making.
  • The partnership combines Trinity's commercial analytics expertise with Ontada's iKnowMed electronic health record system, which contains data from over 2.4 million patient records across 80+ tumor types.
  • The collaboration aims to accelerate commercial decision-making in community oncology through AI-enhanced analytics and deeper patient journey insights.
  • Ontada's real-world data platform serves more than 2,400 oncology community-based providers across the United States through The US Oncology Network and Onmark practices.

Artera's AI Algorithm Identifies Which Prostate Cancer Patients Benefit from Intensive Therapy, Earning Best of ASCO Recognition

AIPrecision Medicine
  • Artera's multimodal AI algorithm successfully identified that only 25% of high-risk prostate cancer patients derive meaningful benefit from androgen receptor pathway inhibitor intensification, potentially sparing 75% from unnecessary toxicities.
  • The company's oral presentation was selected for Best of ASCO 2025, representing the first validated AI algorithm to personalize treatment decisions for high-risk, non-metastatic prostate cancer patients.
  • The ArteraAI Prostate Test works with routine pathology and clinical data without requiring extra tissue or complex molecular testing, making it broadly scalable and cost-effective for clinical implementation.

Transcripta Bio Partners with Microsoft Research to Accelerate AI-Driven Disease Gene Discovery

AIDrug Discovery
  • Transcripta Bio announced a research collaboration with Microsoft Research to accelerate disease-gene association discovery using AI and large-scale transcriptomic data.
  • The partnership combines Transcripta Bio's proprietary Drug-Gene Atlas containing over a billion gene responses with Microsoft Research's machine learning expertise.
  • The collaboration aims to identify novel therapeutic opportunities faster than conventional methods by analyzing chemotranscriptomic datasets for disease-gene associations.
  • Microsoft Research will focus on rare disease genomics while Transcripta Bio contributes its transcriptomics-driven platform for drug discovery acceleration.

Cofactor Genomics' AI-Powered RNA Platform Shows 300-400% Improvement in Predicting Cancer Immunotherapy Response

AIPrecision Medicine
  • Cofactor Genomics' OncoPrism platform demonstrates 300-400% improvement in predicting patient responses to cancer immunotherapies compared to other clinical tests using AI and RNA expression data.
  • The company presented first-time validation results for OncoPrism-NSCLC, showing superior performance over PD-L1 testing with higher sensitivity and specificity in non-small cell lung cancer patients.
  • OncoPrism-HNSCC and OncoPrism-NSCLC are now available for clinical use from Cofactor's CAP-accredited, CLIA-certified laboratory, with Medicare reimbursement approval secured for the head and neck cancer version.

Outcomes4Me Raises $21M to Expand AI-Driven Cancer Care Platform Globally

AIOncology
  • Outcomes4Me secured $21 million in funding led by Salica Investments to accelerate its AI-driven cancer care platform that serves over 280,000 patients.
  • The Boston-based company's platform integrates clinical guidelines, genomics, trial matching, and symptom tracking to help cancer patients navigate their care journey.
  • Seven of the top 10 global cancer pharmaceutical companies are already customers, demonstrating strong market adoption since commercial launch in 2022.
  • The funding will support international expansion, enhanced AI capabilities, and scaling partnerships with health systems and life sciences companies worldwide.

Cardiosense Launches SEISMIC-HF II Study to Validate AI Algorithm for Heart Failure Management

AI
  • Cardiosense has launched SEISMIC-HF II, a nationwide multi-center study to validate its machine learning algorithm for non-invasively assessing intracardiac filling pressure in heart failure patients.
  • The study builds on successful SEISMIC-HF I results that demonstrated accuracy comparable to FDA-approved implantable sensors for estimating pulmonary capillary wedge pressure.
  • Heart failure affects 6.7 million U.S. adults with over $30 billion in annual healthcare costs and nearly 50% readmission rates within six months.
  • The prospective, blinded trial will compare the AI algorithm's non-invasive estimates against invasive right heart catheterization measurements to support regulatory filings.

Illumina Launches PromoterAI Tool to Detect Disease-Causing Mutations in Previously Overlooked Genomic Regions

AIRare DiseasePrecision Medicine
  • Illumina has introduced PromoterAI, an AI tool that detects disease-causing mutations in noncoding promoter regions of the genome, areas typically overlooked in clinical diagnostics.
  • The breakthrough technology, featured in Science, could explain up to 6% of undiagnosed rare disease cases and potentially double diagnostic success when combined with existing AI tools.
  • PromoterAI analyzes promoter sequences using deep learning and is freely available for academic research through Illumina Connected Software, offering precomputed scores to prioritize harmful mutations.

Danaher Partners with AstraZeneca to Develop AI-Powered Precision Medicine Diagnostics

Precision MedicineAI
  • Danaher Corporation has announced a strategic partnership with AstraZeneca to develop and commercialize novel diagnostic tools that will help clinicians identify patients most likely to benefit from precision medicine treatments.
  • The collaboration will leverage Danaher's newly opened Centers for Enabling Precision Medicine and focus initially on digital pathology products and AI-assisted algorithms through subsidiary Leica Biosystems.
  • The partnership aims to address the critical need for precision diagnostics to support next-generation targeted therapies, particularly antibody-drug conjugates, ensuring optimal patient selection for improved treatment outcomes.

AI Test Identifies Prostate Cancer Patients Who Benefit Most from Life-Saving Drug Abiraterone

AIPrecision MedicineOncologyDrug Approval
  • Researchers developed an AI test that can predict which men with high-risk prostate cancer will benefit most from abiraterone treatment by analyzing tumor images.
  • The AI identified that 25% of men with a specific biomarker saw their five-year death risk cut from 17% to 9% when taking abiraterone alongside standard therapy.
  • Men without the biomarker showed no statistically significant benefit from abiraterone, allowing doctors to spare them unnecessary treatment and side effects.
  • The breakthrough could enable NHS England to reconsider funding abiraterone for newly diagnosed high-risk prostate cancer that hasn't spread, potentially helping 2,100 men annually.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.